Skip to main content
SpringerLink
Log in

A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. In this review we consider the evidence for their efficacy and safety in adults with asthma and chronic obstructive pulmonary disease (COPD), by reviewing long-term prospective studies in which these drugs have been compared with placebo or an alternative bronchodilator. We have also assessed safety, including data from postmarketing surveillance studies and case-control studies using large databases.

In patients with asthma, salmeterol and formoterol increase lung function, reduce asthmatic symptoms and improve quality of life when compared with placebo. Both drugs protect against exercise-induced asthma, although some tolerance develops with regular use. Tolerance to the bronchodilator effects of formoterol has also been seen, although this is small and most of the beneficial effects are maintained long-term. Both drugs have been shown to reduce asthma exacerbations but only in studies in which most patients were taking an inhaled corticosteroid. Adding a long-acting β2-agonist provided better control than increasing the dose of inhaled corticosteroid in several studies. Long-acting β2-agonists also provide better asthma control than use of regular short-acting β2-agonists and theophylline. Their relative efficacy compared with leukotriene antagonists is uncertain as yet. Formoterol appears to be at least as safe and effective as a short-acting β2-agonist when used on an ‘as required’ basis.

In patients with COPD, both salmeterol and formoterol offer improved lung function and reduced COPD symptoms compared with placebo, and quality of life has been improved in some studies. Some tolerance to the bronchodilating effect of salmeterol was seen in one study. Most studies have not found a significant reduction in exacerbations in COPD. Both drugs have provided greater benefit than ipratropium bromide or theophylline; there are limited data on tiotropium bromide.

The long-acting β2-agonists cause predictable adverse effects including headache, tremor, palpitations, muscle cramps and a fall in serum potassium concentration. Salmeterol can also cause paradoxical bronchospasm. There is some evidence that serious adverse events including dysrhythmias and life-threatening asthma episodes can occur; however, the incidence of such events is very low but may be increased in patients not taking an inhaled corticosteroid.

Salmeterol 50μg twice daily and formoterol 12μg twice daily are effective and safe in treating patients with asthma and COPD. Higher doses cause more adverse effects, although serious adverse events are rare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Table IV
Table V
Fig. 2
Table VI
Table VII

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Jack D. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other β-adrenoceptor agonists. Br J Clin Pharmacol 1991; 31: 501–14

    Article  PubMed  CAS  Google Scholar 

  2. Anderson GP. Long acting inhaled beta-adrenoceptor agonists. The comparative pharmacology of formoterol and salmeterol. In: New drugs in allergy and asthma. Basel: Birkhauser Verlag, 1993

    Google Scholar 

  3. van Noord JA, Smeets JJ, Raaijmakers JAM, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8

    Article  PubMed  Google Scholar 

  4. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6

    Article  PubMed  CAS  Google Scholar 

  5. O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled β2-agonists in asthma. N Engl J Med 1992; 327: 1204–8

    Article  PubMed  Google Scholar 

  6. Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; I: 554–8

    Article  Google Scholar 

  7. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833–7

    Article  PubMed  CAS  Google Scholar 

  8. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long term treatment with inhaled corticosteroids and beta agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9

    Article  PubMed  CAS  Google Scholar 

  9. Kraan J, Koeter GH, vd Mark TW, et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628–36

    Article  PubMed  CAS  Google Scholar 

  10. Wahedna I, Wong CS, Wisniewski AFZ, et al. Asthma control during and after cessation of regular β2-agonist treatment. Am Rev Respir Dis 1993; 148: 707–12

    Article  PubMed  CAS  Google Scholar 

  11. Hall IP, Tattersfield AE. β-Adrenoceptor agonists. In: Barnes PJ, Rodger IW, Thomson NC, editors. Asthma: basic mechanisms and clinical management. 3rd ed. London: Academic Press, 1999: 651–76

    Google Scholar 

  12. Gardiner PV, Ward C, Booth H, et al. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006–11

    PubMed  CAS  Google Scholar 

  13. Li X, Ward C, Thien F, et al. An antiinflammatory effect of salmeterol, a long-acting β2-agonist, assessed in airway biopsies and bronchoalverolar lavage in asthma. Am J Respir Crit Care Med 1999; 160: 1493–9

    PubMed  CAS  Google Scholar 

  14. Wallin A, Sandström T, Söderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1998; 158: 79–86

    Google Scholar 

  15. Kraft M, Wenzel SE, Bettinger CM, et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997; 111: 1249–54

    Article  PubMed  CAS  Google Scholar 

  16. Jeffery PK, Venge P, Gizycki MJ, et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378–85

    Article  PubMed  CAS  Google Scholar 

  17. Dahl R, Pedersen B, Venge P. Bronchoalveolar lavage studies. Eur Respir Rev 1991; 4: 272–5

    Google Scholar 

  18. Turner MO, Johnston PR, Pizzichini E, et al. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma randomized, placebo controlled trial. Can Respir J 1998; 5: 161–8

    Google Scholar 

  19. Bacci E, Di Franco A, Bartoli ML, et al. Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J 2002; 20: 66–72

    Article  PubMed  CAS  Google Scholar 

  20. Roberts JA, Bradding P, Britten KM, et al. The long-acting β2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275–82

    Article  PubMed  CAS  Google Scholar 

  21. Boulet L-P, Chakir J, Milot J, et al. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clin Exp Allergy 2001; 31: 430–7

    Article  PubMed  CAS  Google Scholar 

  22. Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein coupled receptor via ‘anchored’ agonist binding: molecular localization of the salmeterol exosite within the β2-adrenergic receptor. J Biol Chem 1996; 271: 24029–35

    Article  PubMed  CAS  Google Scholar 

  23. Palmqvist M, Ibsen T, Mellen TI, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244–9

    PubMed  CAS  Google Scholar 

  24. Smyth ET, Pavord ID, Wong CS, et al. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993; 306: 543–5

    Article  PubMed  CAS  Google Scholar 

  25. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201–6

    Article  PubMed  CAS  Google Scholar 

  26. Korosec M, Novak RD, Myers E, et al. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 1999; 107: 209–13

    Article  PubMed  CAS  Google Scholar 

  27. Dollery C, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone, 1999

    Google Scholar 

  28. Bennett JA, Harrison TW, Tattersfield AE. The contribution of the swallowed fraction of an inhaled dose of salmeterol to its systemic effects. Eur Respir J 1999; 13: 445–8

    Article  PubMed  CAS  Google Scholar 

  29. Cheung D, Timmers MK, Zwinderman AH, et al. Long term effects of a long-acting β2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198–203

    Article  PubMed  CAS  Google Scholar 

  30. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235–9

    Article  PubMed  CAS  Google Scholar 

  31. Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma. Am J Respir Crit Care Med 1995; 152: 1170–4

    PubMed  CAS  Google Scholar 

  32. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363–8

    Article  PubMed  CAS  Google Scholar 

  33. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141–6

    Article  PubMed  CAS  Google Scholar 

  34. Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49: 771–4

    Article  PubMed  CAS  Google Scholar 

  35. Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650–6

    Article  PubMed  CAS  Google Scholar 

  36. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four week study of a long-acting β-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178–84

    PubMed  CAS  Google Scholar 

  37. Jones KP. Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. Thorax 1994; 49: 971–5

    Article  PubMed  CAS  Google Scholar 

  38. Boyd G, on behalf of a UK Study Group. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. Eur Respir J 1995; 8: 1494–8

    PubMed  CAS  Google Scholar 

  39. Booth H, Bish R, Walters J, et al. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1995; 51: 1100–4

    Article  Google Scholar 

  40. Wilding P, Clark M, Thompson Coon J, et al. Effect of long term treatment with salmeterol on asthma control. BMJ 1997; 314: 1441–6

    Article  PubMed  CAS  Google Scholar 

  41. Kemp JP, Cook DA, Incaudo GA, et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: 188–95

    Article  PubMed  CAS  Google Scholar 

  42. Lockey RF, DuBuske M, Friedman B, et al. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999; 115: 666–73

    Article  PubMed  CAS  Google Scholar 

  43. Rosenthal RR, Busse WW, Kemp JP, et al. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness. Chest 1999; 116: 595–602

    Article  PubMed  CAS  Google Scholar 

  44. Kemp JP, DeGraff AC, Pearlman DS, et al. A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine. J Allergy Clin Immunol 1999; 104: 1189–97

    Article  PubMed  CAS  Google Scholar 

  45. Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001; 285: 2594–603

    Article  PubMed  CAS  Google Scholar 

  46. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001; 285: 2583–93

    Article  PubMed  CAS  Google Scholar 

  47. D’Urzo AD, Chapman KR, Cartier A, et al. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001; 119: 714–9

    Article  PubMed  Google Scholar 

  48. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062–7

    PubMed  CAS  Google Scholar 

  49. Beach JR, Young CL, Harkawat R, et al. Effect on airway responsiveness of six weeks treatment with salmeterol. Pulm Pharmacol 1993; 6: 155–7

    Article  PubMed  CAS  Google Scholar 

  50. Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148–53

    Article  PubMed  CAS  Google Scholar 

  51. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034–7

    Article  PubMed  CAS  Google Scholar 

  52. Rutten-van Mölken MPMH, Custers F, Vandoorslaer EKA, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8(6): 888–98

    PubMed  Google Scholar 

  53. Faurschou P, Steffensen I, Jacques L, et al. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. Eur Respir J 1996; 9: 1885–90

    Article  PubMed  CAS  Google Scholar 

  54. Boulet L-P, Laviiolette M, Boucher S, et al. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immunol 1997; 99: 13–21

    PubMed  CAS  Google Scholar 

  55. Wenzel SE, Lumry W, Manning M, et al. Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 1998; 80: 463–70

    Article  PubMed  CAS  Google Scholar 

  56. Pearlman DS, Chervinski P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420–5

    Article  PubMed  CAS  Google Scholar 

  57. D’Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412–6

    Article  PubMed  Google Scholar 

  58. Juniper EF, Johnston PR, Borkhoff CM, et al. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med 1995; 151: 66–70

    PubMed  CAS  Google Scholar 

  59. Leblanc P, Knight A, Kreisman H, et al. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am J Respir Crit Care Med 1996; 154: 324–8

    PubMed  CAS  Google Scholar 

  60. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53: 744–52

    Article  PubMed  CAS  Google Scholar 

  61. Kemp J, Wolfe J, Grady J, et al. Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients. Clin Ther 1998; 20: 270–82

    Article  PubMed  CAS  Google Scholar 

  62. Schreurs AJM, Sinninghe Damste HEJ, de Graaff CS, et al. A dose-response study with formoterol Tubuhaler® as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9: 1678–83

    Article  PubMed  CAS  Google Scholar 

  63. van der Molen T, Postma DS, Turner MO, et al. Effects of the long-acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535–9

    Article  PubMed  Google Scholar 

  64. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405–11

    Article  PubMed  CAS  Google Scholar 

  65. van der Molen T, Sears MR, Graaff CS, et al. Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Eur Respir J 1998; 12: 30–4

    Article  PubMed  Google Scholar 

  66. Garcia R, Guerra P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Investig Allergol Clin Immunol 2001; 11: 176–82

    PubMed  CAS  Google Scholar 

  67. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392–7

    PubMed  Google Scholar 

  68. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262–8

    Article  PubMed  Google Scholar 

  69. Price D, Dutchman D, Mawson A, et al. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 2002; 57: 791–8

    Article  PubMed  CAS  Google Scholar 

  70. Wallin A, Melander B, Rosenhall L, et al. Formoterol, a new long-acting β2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259–61

    Article  PubMed  CAS  Google Scholar 

  71. Kesten S, Chapman KR, Broker I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622–5

    Article  PubMed  CAS  Google Scholar 

  72. Arvidsson P, Larsson S, Lofdahl C-G, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168–73

    PubMed  CAS  Google Scholar 

  73. Midgren B, Melander B, Persson G. Formoterol, a new long-acting β2-agonist, inhaled twice daily, in stable asthmatic subjects. Chest 1992; 101: 1019–22

    Article  PubMed  CAS  Google Scholar 

  74. Stalenheim G, Wegener T, Grettve L, et al. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease. Respiration 1994; 61: 305–9

    Article  PubMed  CAS  Google Scholar 

  75. Thomson NC, Angus R, Quebe-Fehling E, et al. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998; 92: 562–7

    Article  PubMed  CAS  Google Scholar 

  76. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999; 103: 427–35

    Article  PubMed  CAS  Google Scholar 

  77. Ekstrom T, Ringdal N, Sobradillo V, et al. Low-dose formoterol Turbuhaler® (Oxis®) bid, a 3-month placebo-controlled comparison with terbutaline (qid). Respir Med 1998; 92: 1040–5

    Article  PubMed  CAS  Google Scholar 

  78. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoteril dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19–27

    Article  PubMed  CAS  Google Scholar 

  79. Newnham DM, Grove A, McDevitt DG, et al. Subsensitivity of bronchodilator and systemic β2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497–504

    Article  PubMed  CAS  Google Scholar 

  80. Fitzpatrick MF, Mackay T, Driver H, et al. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long-acting inhaled β2-agonist. BMJ 1990; 301: 1365–8

    Article  PubMed  CAS  Google Scholar 

  81. Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 μg bid and on-demand salbutamol in moderate persistent asthma. Respir Med 2001; 94: 64–70

    Article  Google Scholar 

  82. McIvor RA, Pizzichini E, Turner MO, et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–30

    PubMed  CAS  Google Scholar 

  83. Selby C, Engleman HM, Fitzpatrick MF, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma? Am J Respir Crit Care Med 1997; 155: 104–8

    PubMed  CAS  Google Scholar 

  84. Pollard SJ, Spector SL, Yancey SW, et al. Salmeterol versus theophylline in the treatment of asthma. Ann Allergy Asthma Immunol 1997; 78: 457–64

    Article  PubMed  CAS  Google Scholar 

  85. Fjellbirkeland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994; 88: 599–607

    Article  PubMed  CAS  Google Scholar 

  86. Paggiaro PL, Giannini D, Di Franco A, et al. Comparison of inhaled salmeterol and individually dose-tritrated slow-release theophylline in patients with reversible airway obstruction. Eur Respir J 1996; 9: 1689–95

    Article  PubMed  CAS  Google Scholar 

  87. Wiegand L, Mende CN, Zaidel G, et al. Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma. Chest 1999; 115: 1525–32

    Article  PubMed  CAS  Google Scholar 

  88. Yurdakul AS, Calisir HC, Tunctan B, et al. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med 2002; 96: 322–9

    Article  PubMed  CAS  Google Scholar 

  89. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075–80

    Article  PubMed  CAS  Google Scholar 

  90. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423–30

    Article  PubMed  CAS  Google Scholar 

  91. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088–95

    Article  PubMed  CAS  Google Scholar 

  92. Ringdal N, Eliraz A, Pruzinec P, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral monetlukast in asthma. Respir Med 2003; 97: 234–41

    Article  PubMed  CAS  Google Scholar 

  93. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327: 891–5

    Article  PubMed  CAS  Google Scholar 

  94. Villaran C, O’Neill SH, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999; 104: 547–53

    Article  PubMed  CAS  Google Scholar 

  95. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern Med 2000; 132: 97–104

    PubMed  CAS  Google Scholar 

  96. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–73

    Article  PubMed  CAS  Google Scholar 

  97. Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14: 627–32

    Article  PubMed  CAS  Google Scholar 

  98. Tattersfield AE, Löfdahl G-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257–61

    Article  PubMed  CAS  Google Scholar 

  99. Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20: 859–66

    Article  PubMed  CAS  Google Scholar 

  100. Pauwels RA, Sears MR, Campbell M, et al. Formoteril as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787–94

    Article  PubMed  CAS  Google Scholar 

  101. Peters JI, Shelledy DC, Jones AP, et al. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. Chest 2000; 118: 313–20

    Article  PubMed  CAS  Google Scholar 

  102. Ritz M, Thorens JB, Arnold-Ketterer M, et al. Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attach. Intensive Care Med 1997; 23: 1225–30

    Article  PubMed  CAS  Google Scholar 

  103. Malolepszy J, Böszörményi Nagy G, Selroos O, et al. Safety of formoterol turbuhaler® at cumulative dose of 90μg in patients with acute bronchial obstruction. Eur Respir J 2001; 18: 928–34

    Article  PubMed  CAS  Google Scholar 

  104. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003; 97: 1067–74

    Article  PubMed  CAS  Google Scholar 

  105. Palmer JBD, Stuart AM, Shepherd GL, et al. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease: a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100μg) with salmeterol (50μg). Respir Med 1992; 86: 409–17

    Article  PubMed  CAS  Google Scholar 

  106. Woolcock A, Lundbak B, Ringdal N, et al. Comparison of the addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153(5): 1481–8

    PubMed  CAS  Google Scholar 

  107. Vervloet D, Ekström T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998; 92: 830–42

    Article  Google Scholar 

  108. Campbell LM, Anderson TJ, Parashchak MR, et al. A comparison of the efficacy of long-acting β2-agonists: eformoterol via Turbohaler® and salmeterol via pressurized metered dose inhaler or Accuhaler®, in mild to moderate asthmatics. Respir Med 1999; 93: 236–44

    Article  Google Scholar 

  109. Condemi JJ. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial. Clin Ther 2001; 23: 1529–41

    Article  PubMed  CAS  Google Scholar 

  110. Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 2002; 121: 1401–6

    Article  PubMed  CAS  Google Scholar 

  111. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750–4

    Article  PubMed  CAS  Google Scholar 

  112. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689–93

    Article  PubMed  CAS  Google Scholar 

  113. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815–21

    PubMed  CAS  Google Scholar 

  114. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283–9

    PubMed  CAS  Google Scholar 

  115. Weiner P, Magadle R, Berar-Yanay N, et al. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnoea in patients with advanced COPD. Chest 2000; 118: 672–8

    Article  PubMed  CAS  Google Scholar 

  116. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002; 9(3): 178–85

    PubMed  Google Scholar 

  117. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, contrlled, 3-month trial. Eur Respir J 2002; 19: 936–43

    Article  PubMed  CAS  Google Scholar 

  118. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084–91

    Article  PubMed  Google Scholar 

  119. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81

    Article  PubMed  CAS  Google Scholar 

  120. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–56

    Article  PubMed  CAS  Google Scholar 

  121. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–9

    Article  PubMed  CAS  Google Scholar 

  122. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–65

    Article  PubMed  CAS  Google Scholar 

  123. Rutten-van Mölken M, Roos B, van Noord JA. An empirical comparison of the St George’s Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995–1003

    Article  PubMed  Google Scholar 

  124. van Noord JA, de Munck DRAJ, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–85

    Article  PubMed  Google Scholar 

  125. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84

    PubMed  CAS  Google Scholar 

  126. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 163: 1087–92

    PubMed  CAS  Google Scholar 

  127. Wadbo M, Löfdahl C-G, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138–46

    Article  PubMed  CAS  Google Scholar 

  128. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55

    Article  PubMed  CAS  Google Scholar 

  129. Di Lorenzo G, Morici G, Drago A, et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther 1998; 20(6): 1130–48

    Article  PubMed  Google Scholar 

  130. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661–70

    Article  PubMed  CAS  Google Scholar 

  131. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–69

    Article  PubMed  CAS  Google Scholar 

  132. D’Urzo AD, Cristina De Salvo M, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347–56

    Article  PubMed  Google Scholar 

  133. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97: 1014–20

    Article  PubMed  CAS  Google Scholar 

  134. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138(4): 850–5

    Article  PubMed  CAS  Google Scholar 

  135. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70–4

    Article  PubMed  CAS  Google Scholar 

  136. Tötterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via turbuhaler® for 3 days in stable asthmatic patients. Eur Respir J 1998; 12: 573–9

    Article  PubMed  Google Scholar 

  137. Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817–24

    Article  PubMed  CAS  Google Scholar 

  138. Chervinsky P, Goldberg P, Galant S, et al. Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial. Chest. 1999; 115: 642–8

    Article  PubMed  CAS  Google Scholar 

  139. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411–5

    Article  PubMed  CAS  Google Scholar 

  140. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993; 87: 227–8

    Article  PubMed  CAS  Google Scholar 

  141. Wilkinson JRW, Roberts JA, Bradding P, et al. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. BMJ 1992; 305: 931–2

    Article  PubMed  CAS  Google Scholar 

  142. Shaheen MZ, Ayres JG, Benincasa C. Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. Eur Respir J 1994; 7: 2160–4

    Article  PubMed  CAS  Google Scholar 

  143. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996; 49: 247–50

    Article  PubMed  CAS  Google Scholar 

  144. Wilton LV, Shakir SA. A postmarketing surveillance study of formoterol (Foradil®). Drug Saf 2002; 25: 213–23

    Article  PubMed  Google Scholar 

  145. US Food and Drug Association. Letters from GlaxoSmithKline Jan 2003, Aug 2003 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2003/serevent [Accessed 2004 Jun]

  146. US Food and Drug Association. Labeling changes for drug products that contain salmeterol. FDA talk paper TO3-62 Aug 14, 2003 [online]. Available from URL: http://www.fda.gov/topics/2003/ANS01248.html [Accessed 2004 Jun]

  147. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 683–6

    Article  PubMed  CAS  Google Scholar 

  148. Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53: 7–13

    Article  PubMed  CAS  Google Scholar 

  149. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160: 594–9

    PubMed  CAS  Google Scholar 

  150. Wareham NJ, Harrison BDW, Jenkins PF, et al. A district confidential enquiry into deaths due to asthma. Thorax 1993; 48: 1117–20

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Sovani is currently running a study funded by AstraZeneca. All three authors have had financial support from pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Schering-Plough) to attend meetings or, in the case of Dr Tattersfield and Dr Whale, for giving talks. Dr Tattersfield had a consultancy recently with Schering-Plough.

Author information

Authors and Affiliations

  1. Division of Respiratory Medicine, City Hospital, Clinical Sciences Building, Nottingham, NG5 1PB, UK

    Milind P. Sovani, Christopher I. Whale & Anne. E. Tattersfield

Authors
  1. Milind P. Sovani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher I. Whale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne. E. Tattersfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milind P. Sovani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sovani, M.P., Whale, C.I. & Tattersfield, A.E. A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease. Drug-Safety 27, 689–715 (2004). https://doi.org/10.2165/00002018-200427100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427100-00001

Keywords

Search

Navigation